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Recombinant human cyclophilin has been co-crystallised with a number of peptides to give crystals uitable for X-ray analysis. The crystal com- 
plexes for which heavy-atom derivatives havebeen prepared and X-ray data collected are: cyclophilin with N-acetyl-Ala-Ala-Pro-Ala-amidomethyl- 
coumarin (I) which crystallises in space group P2,2,2, with a = 108.2, b= 123.0, c= 35.8 A, and cyclophilin with cyclosporin (II) which crystallises 
as tetragonal plates in space group P4,2,2 or P4,2,2 with a = b = 94.98, c = 278.55 A. 
Cyclophilin; Cyclosporin; Protein crystallisation; Cis-truns isomerase; Linear dichroism 
1. INTRODUCTION 
Cyclophilin is a ubiquitous cytosolic protein 
(Mr = 18 000) with a high affinity for the immunosup- 
pressant drug cyclosporin A (Sandimmun) [l]. 
Cyclophilin has also been shown to have peptidyl-pro- 
lyl cis-trans isomerase activity and can accelerate the 
refolding of several proteins in vitro [2,3]. 
Cyclosporin A (II) is a cyclic undecapeptide fungal 
metabolite which is used to prevent graft rejection after 
transplant surgery. The exact biochemical mechanism is 
unknown, though it inhibits the initial steps in T-cell ac- 
tivation and suppresses the expression of interleukin-2 
[4]. It is still not proven that specific cyclosporin-cy- 
clophilin binding is the principal mode of action for 
cyclosporin activity, though it has been shown that in 
lower eukaryotes Neurospora crassa and Sac- 
charomyces cerevisiae, cyclophilin mediates a cytotoxic 
cyclosporin A effect [5]. It seems, therefore, that 
cyclophilin is indeed a specific and biologically relevant 
receptor for cyclosporin, but it is still difficult to ex- 
plain how such a ubiquitous protein provides a specific 
target for an immunosuppressive drug in T- 
lymphocytes. It is also not yet clear how relevant the 
cis-trans isomerase activity is in the mechanism. This 
activity is inhibited by cyclosporin A, and it may be 
significant that the chemically unrelated immunosup- 
pressant FK506 also inhibits the cis-trans prolyl 
isomerase activity of another cytosolic protein, 
macrophilin [6,7]. 
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The 3-D structure of cyclophilin and its complexes 
with peptides, including cyclosporin A, should provide 
an insight into the mechanism of enzymatic action and 
also provide a template for the design of novel drugs 
which may mimic or improve the action of cyc- 
losporin A. 
2. MATERIALS AND METHODS 
2.1. Crystallisation 
Large quantities of pure recombinant human cyclophilin were ob- 
tained using a novel affinity chromatography procedure [s]. Most 
tetrspeptides were obtained from Bachem AG, Bubendarf, 
Switzerland. All crystWsation experiments were carded out using the 
hanging drop methed in Corning 24-well tissue culture plates at room 
temperature. 14 &hops were equilibrated against 1 ml precipitant 
solution. Most trials were carried out using an ICN robot pipetting 
station with software developed in-house. 
2.2. Absorption spectroscopy 
Absorption spectra with linearly polarised light were recorded using 
a Zeiss microspectrometer 03. Spectra were taken in the wavelength 
range from 270 to 550 nm, with a step size of 2 nm (bandwidth 5 nm). 
A small needle-like crystal was inserted between two quartz slides 
which were separated by glass cover slips. Baselines were recorded in 
a region of mother liquor. 
2.3. Density measurements 
The Ficoll density gradient method [9] was used. Ficoll400 (Phar- 
macia) solutions were layered in fractions of decreasing density in a 
glass tube (inner diameter 2 mm). The gradient was smoothed by cen- 
trifugation and crystals were placed at the top of the gradient with a 
drop of mother liquor. The tube was spun at about 1000 x g and the 
position of the crystal in the tube was measured as a function of time 
(up to one hour). The gradient was calibrated over 5 points, with 
drops of a mixture of chloroform and toluene (both of which had 
been saturated with water). For each of the five different 
chloroform/toluene mixtures, the density was determined pyc- 
nometrically. 
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2.4. X-ray diffraction measurements 
Crystals were mounted and sealed in Debye-Scherrer glass capillary 
tubes (0.01 mm thickness) with a plug of well solutian. The X-ray 
source for photographic and area detector studies was an FRS71 
rotating anode generator (Drift ~nstruments~ Ddftr, Holland) run at 
40 kV, ?O mA. Data were collected on an Enraf-Nonius FAST area 
detector system and also on an image plate using the DESY syn- 
chrotron source (in collaboration with Drs C. Betzel and K. Wilson). 
3. RESULTS AND DISCUSSION 
long needles (0.005 x 0.005 x 2.0 mm3) with the follow- 
ing initial conditions: Well: 100 mM imidazole-HCI, 
pH 6.5, 46% saturated ammonium sulphate (AS), 
(saturated at 2O*C), 0.04% (w/v) sodium azide; Drop?: 
25 mM imidazole-HCf, pH 6.5, 12.5% saturated AS, 
0.01% sodium azide, 0.8 mM cyclophilin. 
Much better crystals were obtained by co-crystallising 
cyclophilin with a variety of tetrapeptides which are 
likely substrates for the cis-t’rans isomerase activity. 
We& 100 mM Tris-HCl, pH 8.2, 466% saturated AS, 
0.04~0 sodium azide; K&q?: 50 mM Tris-HCl, pH 8.2, 
42% saturated AS, 0.02Q70 sodium azide, 6 mM 
tetrapeptide, 0.6 mM cyclophilin, 5% methanol. 
The small concentration difference in AS between 
drop and well was found to be important for good 
crystal growth [IO]. The standard 50% dilution of 
precipitant in the drop only gave precipitate. Fig. 1 
shows a typical crystal of cyclophilin complexed with 
the peptide Ac-AAPA-amidomethylcoumarin (I). 
Crystal dimensions can reach 0.2x 0.3 x 1.5 mm3. 
They have space group P21212i with cell dimensions 
a= 108.2, b= 123.0, c=35.8 A and diffract to better 
than 2.4 A resolution. A full native and two useful 
heavy-atom derivative data sets have been collected for 
this crystal form. Absorption spectroscopy was used to 
examine the crystals and to test for the presence of the 
Fig. 1. A crystal of the complex of cyciophilin with Ac-AAPA- 
amidomethylcoumarin (I) (approximate dimensions 0.3 x 0.3 x 3.0 
mm’). The crystal is lying on a face of the (I IO)-form. The needle axis 
is parallel to the c-axis of the unit cell. The bar represents 0.2 mm. 
coumarin group. The prominent faces (Fig, I) were 
identified as belonging to the (1 IO)-form by measuring 
the interfacial angles. 
Absorption spectra were measured with light which 
was linearly polarised parallel and normal to the needle 
axis c in the (Ill))-face. The spectra (Fig. 2) clearly 
demonstrate that the coumarin chromophore (giving 
rise to the 330 nm band) is oriented in the crystal in- 
dicating that the tetrapeptide (I) is bound in a specific 
way to cyclophilin. 
3.2. C.~c~~~~irin-eycrczsfloPin crag& ~~~~~e~e~ 
Three distinct crystal forms of a cyclophilin- 
cyclosporin A complex were obtained. The conditions 
used for crystal growth were: Well: 100 mM Tris-HCl, 
pH 8.2, 48% saturated AS, 0.04% sodium azide, 10% 
DMSO, isopropanol (2.0%, 2.2%, 2.4%); LIrop: 50 
mM Tris-HCl, pH 8.2, 422% saturated AS, 0.02% 
R 
Fig. 2. A linear-dichroism absorption spectrum taken from a single 
crystal of the A~-AA~A-amidomethy~co~marin compIex lying on a 
(I lO)-face. Absorbance is plotted against wavelength (nm). The full 
and dotted lines are spectra obtained for linearly polarised light 
parallel to and perpendicular to the needle axis, respectively. 
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Fig. 3. (a) Bipyramidal crystal of the cyclophilin-cyclosporin com- 
plex. The bar represents 0.25 mm. (b) Rhombohedral crystal of the 
cyclophilin-cyclosporin complex. The bar represents 0.3 mm. (c) 
Tetragonal crystal of the cyclophilin-cyclosporin complex. The bar 
represents 0.17 mm. 
sodium azide, 0.5 mM cyclophilin, 0.5 mM cyclosporin, 
5.3% DMSO. 
Crystals formed within 5 days. The exact quantities 
of both DMSO and isopropanol, and also the small 
difference of AS concentration between drop and well, 
were all found to be critical for the formation of the 
crystals. The hexagonal bipyramidal form (Fig. 3a), the 
rhombohedral form (Fig. 3b) and the tetragonal form 
(Fig. 3c), grew in the presence of 2%, 2.2% and 2.4% 
isopropanol, respectively. In some drops all 3 crystal 
forms were found to grow together. 
The tetragonal form is the most suitable for detailed 
crystallographic study. A multiple seeding technique 
was used to obtain suitably large crystals. After 3-4 
weeks thick, square plates or truncated tetragonal 
pyramids up to 1.5 x 1.5 x 0.2 mm3 had developed. The 
crystals have the space group P412r2 or P&212 with 
a = b = 94.98, c = 278.55 A and diffract to better than 
3 A. 
A native data set to 2.8 A as been collected using the 
DESY synchrotron source, and low resolution (5.5 A) 
heavy-atom derivative data have been collected on a 
FAST area detector. 
time (minutes) 
Fig. 4. Apparent density of the bipyramidal form of cyclophilin com- 
plexed with cyclosporin as a function of time. 
3.3. Crystal density measurements 
Crystal densities of cyclophilin complexed with both 
cyclosporin A and the tetrapeptide have been ex- 
perimentally measured using the Ficoll method. 
Assuming a density of 1 g/cm3 for solvent regions 
and a partial specific volume for the protein of 0.737 
g - ’ . cm’, the number of molecules per cell (n) can be 
calculated from 
n=2.324 (V/M) (QC- 1) 
where V is the cell volume and A4 is the molecular 
weight. 
Crystal density (Q~) is estimated by flotation in a 
Ficoll density gradient and the initial density is obtained 
by extrapolation to time zero. It has been observed that 
for less densely packed crystals, the Ficoll method leads 
to an increase of the apparent crystal density as a func- 
tion of time [l 11, presumably due to an inclusion of, 
Ficoll into the lattice. This was clearly the case for 
cyclophilin complexed with cyclosporin A in which the 
crystal density (ec) rose from 1: 15 to 1.18 g/cm3 after 
40 min (Fig. 4). 
The tetragonal form of cyclophilin complexed with 
cyclosporin A has a unit cell volume of 2 5 13 000 A3. 
The molecular mass of cyclophilin is 18 012 Da and the 
molecular mass of cyclosporin A is 1202 Da. The 
measured density of 1.15 1 g/cm3 gives a calculated sol- 
vent content of 58% with 45.9 cyclophilin-cyclosporin 
A heterodimers in the unit cell. Spacegt oups P4,2r2 and 
I’43212 have 8 asymmetric units per cell which would be 
consistent with either 6 (for n = 48) or 5 (for n = 40) 
heterodimers per asymmetric unit. Six cyclophilin-cy- 
closporin A heterodimers would give 55Vo solvent con- 
tent and a r/, of 2.72 A3/Da; five heterodimers would 
give 63% solvent content and a V,,, of 3.27 A3/Da. 
For the cyclophilin-Ac-AAPA-aminomethylcouma- 
rin complex (V= 476 400 A3, IV,= 18 012 + 527 Da), 
the measured density of 1.155 g/cm3 is consistent with 
n = 9.5 and a solvent content of 57%. This indicates 8 
molecules per cell and a Vm of 3.29 A3/Da and a 
calculated solvent content of 62%. For space group 
P212121 this requires two crystallographically indepen- 
dent molecules per asymmetric unit. 
4. CONCLUSION AND FUTURE WORK 
K-ray diffraction data from native and heavy-atom 
derivative crystals of cyclophilin complexed with Ac- 
AAPA-amidomethylcoumarin have been used to 
calculate an electron density map to 3A and chain trac- 
ing is underway. The more difficult crystallographic 
problem of the complex of cyclophilin with cyclosporin 
A which has 5 or 6 molecules per asymmetric unit, will 
be tackled using molecular replacement techniques once 
a model of cyclophilin becomes available. These struc- 
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tureg will be abte to answer a number of important 
questions concerning the action of cyclosporin A. First- 
ly, it will be possible to determine the conformation of 
bound cyclosporin. A number of crystal structures of 
different chemical derivatives of cyclosporin A tend to 
show the same nonformation [12], however, recent 
NMR results [I 3f indicate that a very different ring con- 
formation is present when bound to cyclophilin. An ac- 
curate description of the bound conformation will be of 
considerable use in designing cyclosporin analogues 
which may have immunosuppressant properties. The 
second major question is whether the ris-rrans 
isomerase activity of cy&loph~li~ s b~olog~~~l~ relevant. 
The structure of the bound tetrapeptide substrate 
should provide some clues as to the enzymatic 
mechanism. Comparison of the two crystal structures 
will unambiguously show whether the tetrapeptide and 
cyclosporin A bind to the same site or whether there is 
an allosteric site on cyclophihn, ff the enzymatic action 
is found to be relevant, this would open up a new direc- 
tion in the design of immunosuppressant drugs based 
on enzyme substrate analogues. 
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